User profiles for "author:Chung-Han Lee"

Chung-Han Lee

MSKCC
Verified email at mskcc.org
Cited by 6840

mTOR pathway as a target in tissue hypertrophy

CH Lee, K Inoki, KL Guan - Annu. Rev. Pharmacol. Toxicol., 2007 - annualreviews.org
Recent work has shown that the mTOR (mammalian target of rapamycin) pathway is an
integral cell growth regulator. The mTOR pathway involves two functional complexes …

Update on tumor neoantigens and their utility: why it is good to be different

CH Lee, R Yelensky, K Jooss, TA Chan - Trends in immunology, 2018 - cell.com
Antitumor rejection by the immune system is a complex process that is regulated by several
factors. Among these factors are the quality and quantity of mutational events that occur in …

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

RM Samstein, CH Lee, AN Shoushtari, MD Hellmann… - Nature …, 2019 - nature.com
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …

[PDF][PDF] An integrated metabolic atlas of clear cell renal cell carcinoma

AA Hakimi, ED Reznik, CH Lee, CJ Creighton… - Cancer cell, 2016 - cell.com
Dysregulated metabolism is a hallmark of cancer, manifested through alterations in
metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell …

A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma

T Funakoshi, CH Lee, JJ Hsieh - Cancer treatment reviews, 2014 - Elsevier
Background Vascular endothelial growth factor (VEGF)-targeted therapy is the currently
standard treatment for advanced and metastatic renal cell carcinoma (RCC). Multiple …

[HTML][HTML] Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid …

MH Taylor, CH Lee, V Makker, D Rasco… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Modulation of vascular endothelial growth factor–mediated immune suppression
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 …

CH Lee, AY Shah, D Rasco, A Rao, MH Taylor… - The lancet …, 2021 - thelancet.com
Background Despite advances in the first-line treatment of metastatic renal cell carcinoma
(RCC), there is an unmet need for options to address disease progression during or after …

[HTML][HTML] Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates

CH Lee, MH Voss, MI Carlo, YB Chen… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell
Carcinoma and Genomic Correlates - PMC Back to Top Skip to main content NIH NLM Logo …

[HTML][HTML] PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

RS Herati, DA Knorr, LA Vella, LV Silva, L Chilukuri… - Nature …, 2022 - nature.com
Abstract Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell
responses in patients with cancer but PD-1 is also expressed by other immune cells …

Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53

CH Lee, K Inoki, M Karbowniczek, E Petroulakis… - The EMBO …, 2007 - embopress.org
Miscoordination of growth and proliferation with the cellular stress response can lead to
tumorigenesis. Mammalian target of rapamycin (mTOR), a central cell growth controller, is …